AFTER the definition of lymphogranuloma venereum as a clinical entity in 19131 and the development of a diagnostic skin test in 1925,2 the disease received wide recognition and numerous therapeutic agents were used in attempts to cure it. Indifferent results were obtained until the advent of sulfanilamide, which proved encouraging in the experience of early investigators.3 Although later reports of the cumulative experience were less optimistic,4 administration of the sulfonamides remained the treatment of choice, since some virustatic properties were demonstrated and secondary infection was controlled. Penicillin showed slight promise,4a, d and streptomycin has had little clinical trial.
The discovery of aureomycin5 and the demonstration of its activity against rickettsias and certain virus infections6 led to the early clinical trial of this agent in the treatment of lymphogranuloma venereum by Wright and his associates.7 They reported the early results in the treatment
FLETCHER A, SIGEL MM, ZINTEL HA. AUREOMYCIN THERAPY IN LYMPHOGRANULOMA VENEREUM. AMA Arch Surg. 1951;62(2):239-250. doi:10.1001/archsurg.1951.01250030244006